Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment
- 1 November 2013
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 133 (11) , 2576-2584
Abstract
No abstract availableKeywords
Funding Information
- Agencia Nacional de Promoción Científica y Tecnológica
- Fundación Bunge y Born (2P50CA101955)
- Consejo Nacional de Investigaciones Científicas y Técnicas
This publication has 38 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- The development of MDA-7/IL-24 as a cancer therapeuticPharmacology & Therapeutics, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Regulation of gene expression via the core promoter and the basal transcriptional machineryDevelopmental Biology, 2010
- Adenoviral targeting of gene expression to tumorsCancer Gene Therapy, 2010
- Immunotherapy of distant metastatic diseaseAnnals of Oncology, 2009
- Hypoxia, melanocytes and melanoma – survival and tumor development in the permissive microenvironment of the skinPigment Cell & Melanoma Research, 2009
- In vitro evaluation of cancer-specific NF-κB-CEA enhancer–promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell linesBritish Journal of Cancer, 2007
- CMV enhancer/human PDGF-β promoter for neuron-specific transgene expressionGene Therapy, 2003
- High and Sustained Transgene Expression in Vivo from Plasmid Vectors Containing a Hybrid Ubiquitin PromoterMolecular Therapy, 2001